The methodological quality is insufficient in clinical practice guidelines in the context of COVID-19 : systematic review by Stamm, T.A. et al.
This is a repository copy of The methodological quality is insufficient in clinical practice 
guidelines in the context of COVID-19 : systematic review.




Stamm, T.A., Andrews, M.R., Mosor, E. et al. (20 more authors) (2021) The methodological
quality is insufficient in clinical practice guidelines in the context of COVID-19 : systematic 





This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Journal of Clinical Epidemiology 135 (2021) 125–135 
The methodological quality is insufficient in clinical practice guidelines 
in the context of COVID-19: systematic review 
Tanja A. Stamm a , s , ∗, Margaret R. Andrews a , Erika Mosor a , Valentin Ritschl a , Linda C. Li b , c , 
Jasmin K. Ma b , c , Adalberto Campo-Arias d , Sarah Baker e , Nicola W. Burton f , 
Mohammad Eghbali g , Natalia Fernandez h , Ricardo J.O. Ferreira i , Gabriele Gäbler j , 
Souzi Makri k , Sandra Mintz l , Rikke Helene Moe m , Elizabeth Morasso n , Susan L. Murphy h , 
Simiso Ntuli o , Maisa Omara a , s , Miguel Angel Simancas-Pallares p , Jen Horonieff q , 
Gerald Gartlehner r , t 
a Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria 
b Department of Physical Therapy, University of British Columbia, Vancouver, British Columbia, Canada 
c Arthritis Research Canada, Richmond, British Columbia, Canada 
d Medicine Program, Faculty of Health Sciences, University of Magdalena, Santa Marta, Colombia 
e Unit of Oral Health, Dentistry and Society, School of Clinical Dentistry, University of Sheffield, Sheffield, UK 
f School of Applied Psychology, Griffith University, Mt. Gravatt, Australia 
g Department of Nursing, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 
h Department of Physical Medicine and Rehabilitation, University of Michigan and VA Ann Arbor Health Care System, Ann Arbor, MI, USA 
i Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal 
j Austrian Association of Dietitians, Vienna, Austria 
k The Cyprus League Against Rheumatism and Platform Organization for People for Rheumatic Diseases in Southern Europe, Nicosia, Cyprus 
l Office of Patient Experience, Children’s Hospital Los Angeles, Los Angeles, CA, USA 
m Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway 
n Department of Radiation Oncology, UCLA Health, Los Angeles, CA, USA 
o Department of Podiatry, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa 
p Division of Pediatric and Public Health, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA 
q Savvy Cooperative, Queens, NY, USA 
r Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems an der Donau, Austria 
s Ludwig Boltzmann Institute for Arthritis and Rehabilitation, 1090, Vienna, Austria 
t RTI International, Research Triangle Park, NC, USA 
Received 9 November 2020; Received in revised form 15 February 2021; Accepted 3 March 2021; Available online 7 March 2021 
Objectives: The number of published clinical practice guidelines related to COVID-19 has rapidly increased. This study explored if 
basic methodological standards of guideline development have been met in the published clinical practice guidelines related to COVID-19. 
Study Design and Setting: Rapid systematic review from February 1 until April 27, 2020 using MEDLINE [PubMed], CINAHL 
[Ebsco], Trip and manual search, including all types of healthcare workers providing any kind of healthcare to any patient population 
in any setting. 
Results: There were 1342 titles screened and 188 guidelines included. The highest average AGREE II domain score was 89% for 
scope and purpose , the lowest for rigor of development (25%). Only eight guidelines (4%) were based on a systematic literature search 
and a structured consensus process by representative experts (classified as the highest methodological quality). The majority (156; 83%) 
was solely built on an informal expert consensus. A process for regular updates was described in 27 guidelines (14%). Patients were 
included in the development of only one guideline. 
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Conclusion: Despite clear scope, most publications fell short of basic methodological standards of guideline development. 
Clinicians should use guidelines that include up-to-date information, were informed by stakeholder involvement, and employed rigorous 
methodologies. 
© 2021 Medical University of Vienna. Published by Elsevier Inc. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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What is new? 
Key findings 
• Despite clear scope, most guidelines for SARS 
CoV-2 infections and for other care in the con- 
text of COVID-19 fell short of basic methodologi- 
cal standards. Only 4% were based on a systematic 
literature search and a structured consensus process 
by representative experts (classified as the highest 
methodological quality). Patients were included in 
the development of one guideline. A process for 
regular updates was described in 14%. 
What this adds to what is known? 
• Our study explored if basic methodological stan- 
dards of guideline development have been met in 
the published clinical practice guidelines related to 
COVID-19. 
What is the implication/what should change now? 
• An insufficient consideration of appropriate 
methodologies in the guideline development 
process could lead to misleading information, un- 
certainty among the professionals, and potentially 
harmful actions for patients. This paper provides 
an important benchmark for the future assessment 
of the quality of COVID-19 guidelines. 
1. Introduction 
The novel Coronavirus Disease 2019 (COVID-19) 
spread rapidly worldwide and the number of cases in- 
creased globally at an accelerated rate [1 , 2] . While mea- 
sures are essential to mitigate the impact of the pandemic 
specifically, we also need immediate and targeted action to 
continue effective and safe healthcare generally. Necessary 
actions to avoid collateral damages to patients range from 
adapting healthcare to maximizing safety while providing 
continuation of usual healthcare to rapidly restart routine 
care in the areas where healthcare has been reduced due 
to mandated lockdowns. Moreover, healthcare workers in 
close physical contact with patients could be infected or 
could be unknowingly carriers of the SARS-CoV-2 virus 
themselves. 
Clinical practice guidelines and recommendations are 
needed to support therapeutic decisions and provide an es- 
sential knowledge source, especially in such a new and 
challenging situation. Clinical practice guidelines are state- 
ments that include recommendations intended to optimize 
patient care which are informed by a systematic review of 
evidence and an assessment of the benefits and harms of 
alternative care options [3 , 4] . 
The number of published guidelines and recommen- 
dations related to COVID-19 has rapidly increased since 
February 2020. However, insufficient consideration of ap- 
propriate methodologies and rigorous strategies in the 
guideline development process could lead to misleading 
information, uncertainty among professionals, and poten- 
tially harmful actions for patients [4 , 5] . The aim of our 
study was therefore to systematically review and critically 
appraise clinical practice guidelines related to SARS-CoV- 
2 infections and the delivery of healthcare in the current 
context of COVID-19 from a methodological perspective. 
2. Methods 
2.1. Data sources and searches 
We performed a rapid systematic review informed by 
the Cochrane Rapid Reviews Interim Guidance from the 
Cochrane Rapid Reviews Methods Group [6] in collab- 
oration with Cochrane Austria. We will provide yearly 
updates during the pandemic and thereafter, as appropri- 
ate, given the currently increasing evidence and the rising 
number of published guidelines in the context of COVID- 
19. An international expert task force including representa- 
tives from each of the six WHO regions (Europe, America, 
Africa, Eastern-Mediterranean, South-East Asia, Western- 
Pacific) defined research questions, keywords, Medical 
Subject Headings (MeSH) terms and a search strategy for 
the rapid systematic review. We searched the MEDical 
Literature Analysis and Retrieval System OnLINE (MED- 
LINE) [PubMed], the Cumulative Index to Nursing & Al- 
lied Health Literature (CINAHL) [Ebsco] and the Turn- 
ing Research Into Practice (Trip) database on April 27, 
2020 (calendar week 17) for medical guidelines and rec- 
ommendations in the context of the COVID-19 pandemic 
published after February 1, 2020. An initial limited search 
was conducted to verify our selection of search terms and 
proposed strategy. The results of the initial pilot search 
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were discussed with the task force. The search strategy 
( Supplement Table A ) was adapted accordingly and ap- 
proved before conducting the literature search in MED- 
LINE, CINAHL and Trip. To identify grey literature [7] , 
the task force members were asked to indicate any addi- 
tional guidelines and recommendations not identified in the 
database queries. In addition, we examined the websites 
of cross-regional associations and institutions at continent 
level. The study protocol is publicly available at www. 
researchgate.net (DOI:10.13140/RG.2.2.21293.51689). All 
task force members completed conflict of interest 
forms. 
2.2. Study selection 
Inclusion criteria were (i) guidelines and recommenda- 
tions related to the COVID-19 situation, (ii) all types of 
healthcare workers providing any kind of healthcare to any 
patient population, (iii) any setting (acute care, rehabilita- 
tion, long-term care, practice, home visits, etc.). We did not 
restrict to any specific authors, e.g. from a certain group of 
health professionals. We excluded documents that only dis- 
cuss (i) infection control and exposure safety information, 
(ii) experimental pharmaceutical treatments, (iii) clinical 
research recommendations, (iv) ethical guidelines, (v) di- 
agnostic procedures or strategies, (vi) results not produced 
in direct relation to the COVID-19 situation, (vii) text- 
books, theoretical exercises, case studies, experience write- 
ups, and (viii) documents not available in English. 
Results from the searches in MEDLINE and CINAHL 
were downloaded in Covidence ( www.covidence.org ) 
and duplicates removed thereafter. One reviewer (MA) 
screened titles and abstracts for basic inclusion and ex- 
clusion criteria as described above. To ensure accuracy of 
the selection process, 60 percent of the titles and abstracts 
were independently screened by other reviewers (EMos, 
VR, TS). Disagreements were resolved through consen- 
sus. Reasons for exclusion are provided in a Preferred Re- 
porting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flowchart [8] in Figure 1 and in more detail in 
the supplementary material ( Supplement Table B ). Follow- 
ing a training session, full text screening was carried out by 
at least two reviewers per document (MA, LL, EMos, JM, 
MO, VR, TS). For the planned updates (living review), we 
will use automated text mining (tm) based on the tm pack- 
age in R ( www.r-project.org ) to support abstract screening 
and study selection. 
2.3. Data extraction and quality assessment 
Data extracted included study characteristics 
( Supplement Table C ), a critical appraisal according 
to The Appraisal of Guidelines for Research & Evaluation 
Instrument (AGREE II) [5] and classification of the 
guidelines according to the Association of the Scientific 
Medical Societies (AWMF) Guidance Manual and Rules 
for Guideline Development [9] . The AGREE II is the 
gold-standard protocol for clinical guideline assessment, 
development, and reporting [5] . It comprises 23 items 
assessing six domains including scope and purpose, 
stakeholder involvement, rigor of development, clarity 
of presentation, applicability, and editorial independence. 
The AWMF Guidance Manual and Rules for Guideline 
Development classifies guidelines as being based either on 
(i) a systematic literature review including a subsequent 
synthesis of the evidence and a structured consensus 
process completed by a representative committee (S3), 
(ii) a systematic literature review and synthesis of the 
evidence only (S2e), (iii) a structured consensus process 
completed by a representative committee only (S2k) or 
(iv) an informal consensus process by a group of experts 
(S1) [9] . 
Reviewers pilot-tested the data extraction form on 19 
(10%) of the records ( Supplement Table C ) then indepen- 
dently extracted the data. AGREE II scores were ranked 
on a Likert scale from 1 = strongly disagree to 7 = strongly 
agree. Mean scores between the two reviewers were cal- 
culated for each AGREE II item. AGREE II items were 
summarized into the six domain scores [5] . An overall rat- 
ing and a qualitative recommendation were assigned and 
disagreements were resolved through consensus. AGREE 
domain-level scores were calculated for each publication 
and mean domain-level scores were formed for the entire 
dataset and the S3 guidelines separately. 
2.4. Data synthesis and analysis 
Descriptive statistics were calculated for relevant extrac- 
tion fields for the entire dataset using Microsoft Excel, in- 
cluding geographic affiliation of authors, publication status, 
type of recommendation, target population, focus of recom- 
mendation, disease/condition, and setting. Other fields are 
presented narratively, where appropriate. The world map 
was created in the Free and Open Source Geographic In- 
formation System QGIS ( https:// qgis.org/ en/ site/ ). We used 
the PRISMA checklist for standardized reporting in sys- 
tematic reviews and meta-analyses as a reference for the 
reporting of our results ( Supplement Table F ). 
3. Results 
In total, we identified 819 records in MEDLINE, 89 
in CINAHL and 434 in Trip through our systematic 
search, and four additional records through other sources 
( Fig. 1 ). We retained 397 documents for abstract and full 
text screening. Of these, 188 guidelines and recommenda- 
tions met the inclusion criteria and were selected for data 
extraction and critical appraisal. 
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Fig. 1. PRISMA chart. 
3.1. Target areas, professionals, and country 
representation of authors 
The most frequent medical areas addressed in the 
guidelines were acute COVID-19 care (n = 46; 24%), 
surgery (n = 41; 22%), oncology (n = 20; 11%), ra- 
diology (n = 14; 7%) and cardiology (n = 10; 5%). 
A third (n = 57; 30%) of the guidelines focused on 
miscellaneous other medical areas ( Supplement Table D ). 
All except four guidelines (184; 98%) targeted physi- 
cians. The four guidelines not targeting physicians re- 
ferred to care delivered by non-physician health profession- 
als, namely pharmacy practice management for hematopoi- 
etic cell transplantation and cellular therapy [10] , phys- 
iotherapy management for COVID-19 in the acute hos- 
pital settings [11] , and two articles on pharmaceutical 
care [12 , 13] . Overall, 84 guidelines (45%) mentioned 
the work of non-physician health professionals. This in- 
cludes naming specific professions and/or grouping all 
non-physician health professionals under members of a 
healthcare team. Thirty-two (17%) guidelines also tar- 
geted patients and/or the general public. Patients were in- 
cluded as reviewers in the development of only one guide- 
line [14] . Experts from 54 countries participated in the 
guidelines development, with Africa being the least repre- 
sented continent and North America being the most rep- 
resented continent ( Fig. 2 and Supplement Table G ). A 
process for regular updates was described in 27 guidelines 
(14%). 
3.2. Critical methodological appraisal 
The highest average AGREE II [5] domain score was 
given for scope and purpose (89%), followed by clarity 
of presentation (70%) and editorial independence (61%). 
Stakeholder involvement was on average fulfilled by 43% 
and applicability by 35%. The lowest average AGREE do- 
main score (25%) was given for rigor of development due 
to the fact that methods of development were insufficiently 
or not reported. The domain scores of each guideline are 
shown in Supplement Table E . The mean overall quality 
rating of the guidelines was 3.8 (standard deviation + /-1.4) 
of a maximum score 7. 
Eight of all 188 guidelines (4%) [11 , 14 –20] were classi- 
fied as having the highest methodological level (systematic 
literature search and structured consensus process by rep- 
resentative experts; S3) [9] ( Table 1 ). Twelve guidelines 
(6%) were solely based on a systematic literature review 
and synthesis of the evidence (S2e), while a further 12 
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ahead of print; 
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to address 14 
questions, 
correspond- 








unclear 7 COVID-19 COVID-19 Chest imaging Generic 
Zhao, Xie, Wang 
[20] (789) 
China 09.04.20 (e-pub 
ahead of print; 
official publication 
in July 2020) 




yes 6.5 COVID-19 COVID-19 Respiratory 
rehabilitation 
Generic 
COVID-19, coronavirus disease 2019; ICU, intensive care unit; UAE, United Arab Emirates; UK, United Kingdom; USA, United States of America. 
Conflict of interest was declared in all these S3 guidelines. Options for comments or external review were not given in any of these. AGREE II scores were ranked on a Likert scale from 
1 = strongly disagree to 7 = strongly agree. We included up-dates of the guidelines until 08.02.2021. 
a This paper itself was not updated, but AGA released a formal recommendation on 11.05.20 titled ‘AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, 
Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19’ with the same purpose [24] . 
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Fig. 2. Country representation of the guideline authors. Absolute and relative frequencies per country are shown in Supplement Table G . 
Fig. 3. Numbers of published guidelines which increased per week separately for each S-level [9] Guidelines were classified according to the Association 
of the Scientific Medical Societies (AWMF) Guidance Manual and Rules for Guideline Development [9] . S3 is a systematic literature review 
including a subsequent synthesis of the evidence and a structured consensus process completed by a representative committee. S2e refers to 
a systematic literature review and synthesis of the evidence only; S2k guidelines are based on a structured consensus process completed by a 
representative committee only. S2e and S2k are summarized in this graph as S2. S1 in this work includes both, documents based on an informal 
consensus process by a group of experts as well as expert opinions. 
completed by a representative committee only (S2k). The 
majority of the guidelines and recommendations, namely 
156 (83%), were developed based on an informal consen- 
sus process by a group of experts (S1). Papers which re- 
ferred to a consensus process or expert opinion without 
providing any details were also assigned to the group of 
S1 guidelines. An overview about the number of published 
guidelines regarding their S-classification is depicted sep- 
arately for each week in Figure 3 . The eight S3 guidelines 
had an average overall quality rating of 6.7 (standard de- 
viation + /-0.5) of a maximum score 7 and are depicted 
Table 2 . 
4. Discussion 
A considerable number of medical guidelines and rec- 
ommendations related to the COVID-19 pandemic were 
published from February to April 2020. Despite high 
AGREE II scores for scope and purpose as well as for 
clarity of presentation , the majority of the guidelines and 
recommendations fell short of basic standards. This was 
mainly due to a lack of appropriate methodologies and 
rigorous strategies in the guideline development process. 
The quality and methodological limitations of the guide- 
lines should be placed in the context of the current un- 
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Table 2. Mean AGREE II domain scores for the eight publications classified as the highest methodological level (systematic literature search and 























































Hooft [16] (302) 
100% 78% 94% 100% 58% 100% 7 Yes 
Alhazzani, 
Møller, Arabi, 
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Yim, Martin [18] 
(613) 
100% 67% 81% 100% 67% 100% 7 Yes 
Zhao, Xie, Wang 
[20] (789) 
100% 56% 65% 67% 75% 50% 6.5 Yes 
AGREE II scores were ranked on a Likert scale from 1 = strongly disagree to 7 = strongly agree. 
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precedented situation and the human resources required to 
produce high-quality guidelines in a timely manner. While 
systematically developed statements reflecting the current 
state of knowledge and supporting health professionals 
in their work during the COVID-19 pandemic have been 
urgently needed, basic methodological standards in the 
guideline development process are nevertheless essential 
to avoid misleading information and potentially harmful 
actions for patients and the healthcare system as a whole. 
One S3 guideline [19] with high overall methodological 
ratings had been published in calendar week six from 
when we found the first guidelines in our search ( Fig. 3 ), 
demonstrating that it was possible to produce high-quality 
work in a short time. Taking more time to develop guide- 
lines therefore may not always lead to a more rigorous 
methodological basis. Rather, the methodological commit- 
ment, expertise of the authors and engagement of appropri- 
ate stakeholders might be important for a rigorous devel- 
opment process, independent of the time period after the 
outbreak when the guideline was published. Many guide- 
lines have been published since the end of April 2020, 
with better knowledge, experience and more robust litera- 
ture accompanying the evolution of the pandemic. Further 
research should monitor the evolving methodological qual- 
ity of the guidelines and their updates over time. Similar 
to our study, a review of prediction models for diagno- 
sis and prognosis of COVID-19 concluded that the pub- 
lished models were poorly reported and at high risk of bias 
[25] . 
Clinical practice guidelines with the highest method- 
ological quality, classified as S3 according to AWMF, are 
built on both a systemic literature review and a structured 
consensus process by representative experts. Only 4% of 
all guidelines in our study were S3. Another 6% reported 
solely a structured consensus process without a systematic 
literature review (classified as S2k according to AWMF). 
The majority (83%) was based on an informal consen- 
sus by a group of experts only. However, even if some 
guidelines developers might argue that well-designed stud- 
ies were lacking at a certain time point and a systemic 
literature review as a basis for the guideline development 
was therefore not conducted, a structured consensus pro- 
cess could still have been done. 
A clear updating process, patient and public involve- 
ment, a systematic development processes incorporating 
systematic review, an explicit recommendation develop- 
ment process (rigor of development domain), and guid- 
ance on implementation of these guidelines (applicability 
domain) are needed areas to improve guideline develop- 
ment quality. Given the increasing evidence related to the 
COVID-19 pandemic, a clear updating process, as well 
as information of where previous and later versions of 
the guideline can be found might be essential information 
which should be explicitly stated in each document. Al- 
though patient and public involvement is recognized as a 
key component of clinical practice guideline development 
[26] , almost no citizens, patients or their public represen- 
tatives were involved in the development of any of the 
documents, except for one guideline [14] . 
Non-physician health professionals provide essential 
care, especially in the area of non-pharmacological inter- 
ventions including physical activity/exercise, activity pac- 
ing, pain management, complex chronic disease manage- 
ment, nutrition, speech/aural care, personal care, disability, 
rehabilitation, substance use, aged care and psychosocial 
health [27] . Some of these interventions have been con- 
tinuously provided during the current COVID-19 situation, 
some health services have not been delivered due to home 
quarantine and physical distancing [28] . Guidelines and 
recommendations on how to manage and respond to this 
situation are often missing. Currently, the majority of the 
published guidelines, which we reviewed, did not focus 
on the specific needs of non-physician health profession- 
als who are usually in direct/face-to-face patient contact. 
However, due to often unclear information about the back- 
ground and role of each author in the guideline devel- 
opment process, transparency on stakeholder involvement 
was sometimes lacking and judgment was left to the dis- 
cretion of the reviewers. Balanced stakeholder involvement 
as well as explicit information about this process in the 
paper would be necessary for a transparent guideline de- 
velopment that takes into account different treatment per- 
spectives. 
Our study focused on quality criteria of the published 
guidelines and recommendations. We did not extract, com- 
pare and synthesize the medical content of the recommen- 
dations, due to the heterogeneity of medical disciplines in- 
cluded in this work. This might be regarded as a limitation 
of our work. Nevertheless, our results might also contribute 
to a further conversation on how best to mobilize national 
and international resources to develop high-quality guide- 
lines in crisis situations in the future. 
5. Conclusion 
A considerable number of medical guidelines and 
recommendations were published in the context of the 
COVID-19 pandemic from February to April 2020. 
Despite high AGREE II scores for scope and purpose 
as well as for clarity of presentation , the majority of 
the guidelines and recommendations fell short of basic 
methodological standards. This was mainly due to a lack 
of appropriate methodologies and rigorous strategies in the 
guideline development process. Updated guidelines should 
include up-to-date information, transparent stakeholder 
involvement, consideration of various patient populations, 
and rigorous strategies and methodologies. Our study 
will allow clinicians to better select and appraise clinical 
practice guidelines. It will create awareness and inspire 
guideline developers, researchers and journal editors to 
focus on methodological accuracy instead of publishing 
large quantities of documents which lack basic method- 
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ological standards. Future research should monitor the 
evolving methodological quality of the guidelines and 
their updates over time. This paper provides an important 
benchmark for the future quality assessment of COVID-19 
guidelines. 
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